Embecta Corp. (NASDAQ:EMBC – Get Free Report)’s stock price passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $6.57 and traded as low as $6.49. Embecta shares last traded at $6.55, with a volume of 1,277,526 shares changing hands.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on EMBC shares. Zacks Research raised shares of Embecta from a “strong sell” rating to a “hold” rating in a research note on Friday, July 17th. Weiss Ratings upgraded shares of Embecta from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, October 9th. Three research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Embecta has a consensus rating of “Reduce” and an average target price of $11.00.
Check Out Our Latest Analysis on Embecta
Embecta Stock Performance
The company’s 50 day simple moving average is $5.67 and its 200 day simple moving average is $6.57.
Embecta (NASDAQ:EMBC – Get Free Report) last released its quarterly earnings results on Friday, August 7th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.29. The company had revenue of $271.70 million for the quarter, compared to the consensus estimate of $254.53 million. The firm’s quarterly revenue was down 8.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. Equities research analysts forecast that Embecta Corp. will post 1.84 earnings per share for the current year.
Embecta Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 15th. Investors of record on Thursday, August 27th were paid a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Thursday, August 27th.
Insider Activity at Embecta
In other news, insider Jeffrey Z. Mann purchased 20,000 shares of the stock in a transaction dated Wednesday, August 12th. The shares were bought at an average cost of $4.99 per share, for a total transaction of $99,800.00. Following the transaction, the insider owned 262,915 shares in the company, valued at $1,311,945.85. This trade represents a 8.23% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Devdatt Kurdikar acquired 30,000 shares of the company’s stock in a transaction dated Wednesday, August 12th. The stock was purchased at an average cost of $4.70 per share, for a total transaction of $141,000.00. Following the purchase, the chief executive officer directly owned 804,919 shares in the company, valued at approximately $3,783,119.30. This represents a 3.87% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 70,000 shares of company stock worth $334,200 over the last ninety days. Insiders own 1.30% of the company’s stock.
Institutional Trading of Embecta
Several institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its stake in Embecta by 101.5% during the third quarter. GAMMA Investing LLC now owns 10,898 shares of the company’s stock valued at $62,000 after buying an additional 5,490 shares in the last quarter. Isthmus Partners LLC grew its holdings in Embecta by 5.5% during the first quarter. Isthmus Partners LLC now owns 146,342 shares of the company’s stock worth $1,294,000 after acquiring an additional 7,613 shares during the period. State of Wyoming grew its holdings in Embecta by 61.5% during the first quarter. State of Wyoming now owns 24,587 shares of the company’s stock worth $217,000 after acquiring an additional 9,366 shares during the period. Quadrant Capital Group LLC bought a new stake in Embecta in the third quarter worth about $62,000. Finally, One Wealth Advisors LLC bought a new stake in Embecta in the second quarter worth about $33,000. Institutional investors and hedge funds own 93.83% of the company’s stock.
About Embecta
Embecta Corp. (NASDAQ: EMBC) is a global diabetes-care company that develops, manufactures and sells products used to administer insulin and monitor blood glucose. Its portfolio includes pen needles, insulin syringes, safety needles and syringes, lancets, and other diabetes-management products designed for people with diabetes and the health care professionals who support them.
The company also offers digital and connected solutions intended to support diabetes management and improve the delivery of care.
Featured Articles
- Five stocks we like better than Embecta
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
